DEA Rules on Cannabis Medical Status as Insurers Exit RICO Exposure

DEA Finalizes Medical Marijuana Classification Rule

The DEA published its final rule on marijuana's Schedule I status on August 25, 2026, concluding a rescheduling proceeding initiated in 2024. The agency's determination follows a two-year administrative review that included public comment periods and expert testimony from the Department of Health and Human Services. The rule addresses whether marijuana meets the Controlled Substances Act criteria for accepted medical use—a threshold required for Schedule II or lower classification.

The final rule takes effect 60 days after Federal Register publication. State-licensed operators in 38 medical cannabis programs will face immediate operational changes depending on the scheduling outcome. Schedule III classification would eliminate Internal Revenue Code Section 280E tax penalties. Schedule II would maintain federal-state licensing conflicts.

Multi-State Operators Face Federal RICO Claims

Trulieve Cannabis, Curaleaf Holdings, and Green Thumb Industries are defendants in consolidated RICO litigation filed in U.S. District Court for the District of Columbia. The civil claims, brought by a coalition of property owners and municipal governments, allege that state-licensed cannabis operations constitute a pattern of racketeering activity under 18 U.S.C. § 1962. Plaintiffs seek treble damages for property value diminution and public nuisance abatement costs.

Court filings reviewed by CannIntel show the complaints cite:

• Violation of the Controlled Substances Act as predicate acts under RICO
• Interstate commerce in Schedule I substances
• Conspiracy to operate continuing criminal enterprises
• Money laundering through state-chartered financial institutions

Defense counsel for the MSOs argue that state regulatory compliance and the Rohrabacher-Farr amendment bar federal prosecution, but RICO's civil provisions operate independently of DOJ enforcement discretion. The D.C. Circuit hasn't yet ruled on motions to dismiss.

Commercial Insurers Withdraw General Liability Coverage

At least seven commercial carriers terminated or declined to renew general liability policies for cannabis operators between June and August 2026, citing RICO exposure as an exclusionary risk. Chubb, Travelers, and Liberty Mutual issued non-renewal notices to state-licensed cultivators and dispensaries, according to insurance broker disclosures. The withdrawals affect an estimated $400 million in annual premium volume.

Underwriters cite two triggers. First, RICO's treble-damage provision creates uncapped liability that exceeds actuarial models for plant-touching businesses. Second, federal illegality clauses in standard Commercial General Liability policies void coverage for activities that violate the Controlled Substances Act, regardless of state licensure.

The insurance pullback leaves operators with captive programs, surplus lines carriers charging 300-500% premium increases, or no coverage at all—a risk profile that makes institutional capital nearly impossible to secure.

Impact on Operator Financing and Valuations

The insurance crisis has frozen $1.2 billion in pending debt and equity raises for U.S. cannabis companies, according to Viridian Capital Advisors data released August 20. Institutional lenders require proof of general liability coverage as a condition precedent to funding. Without it, term sheets expire. Credit facilities enter technical default.

Public MSO valuations declined an average of 18% in August trading. Curaleaf's market cap fell from $3.1 billion to $2.5 billion between August 1 and August 23. Trulieve and Green Thumb saw comparable declines. The sell-off reflects investor repricing of legal and insurance risk that was previously modeled as remote.

State Regulators Face Licensing Dilemma

State cannabis control boards in California, Florida, and Illinois have received requests from operators to waive insurance requirements pending resolution of the federal rescheduling and RICO litigation. The California Department of Cannabis Control hasn't responded to operator petitions filed in July. Florida's Office of Medical Marijuana Use issued an emergency rule on August 15 allowing operators to post surety bonds in lieu of liability coverage, but bonding companies are applying the same exclusions as insurers.

Congressional Response and Safe Banking Act Prospects

Senate Banking Committee Chair Sherrod Brown and Ranking Member Tim Scott released a joint statement on August 22 calling for expedited consideration of the SAFER Banking Act, which passed the House in July 2025 but stalled in the Senate. The bill would prohibit federal banking regulators from penalizing depository institutions that serve state-licensed cannabis businesses. It doesn't address RICO liability or insurance market failures.

House Judiciary Committee Chair Jim Jordan convened a hearing on August 24 examining whether RICO's civil provisions should exclude state-compliant cannabis operators. No legislative text has been introduced. Congressional observers note that any RICO carve-out would require 60 Senate votes, a threshold that cannabis reform bills have never reached.

What Operators Are Watching Next

The next 90 days will determine whether the cannabis industry faces a liquidity crisis or a regulatory reprieve. Three variables are in play. First, the DEA's final rule on scheduling, expected to publish in the Federal Register by September 1. Second, the D.C. Circuit's ruling on the RICO motion to dismiss, with oral arguments scheduled for October 2026. Third, whether state regulators grant insurance waivers or begin license suspensions for non-compliance.

For comprehensive tracking of the DEA rescheduling process and its implications for operators, see the CannIntel topic hub on DEA Rescheduling. The collision of federal reform and civil liability is the defining risk event of 2026 for the U.S. cannabis sector.